Thus, tumor stem cell–derived CD133+ CD326- EVs circulating in peripheral blood could be used in liquid biopsies as biomarkers for early diagnosis and for monitoring the temporal and spatial heterogeneity of tumor cells. This evidence concerns the gene PROM1 and neoplasm.